Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Azenosertib in Uterine Serous Carcinoma: Biomarker Study
Recruiting · NCT06369155 · Registry updated 2026-03-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Azenosertib in Uterine Serous Carcinoma: Biomarker Study | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine cancer, uterine carcinoma, uterine disorder | Recruiting | Phase 2 | 2026-03-02 | NCT06369155 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Joyce Liu, MD | 1 |
| National Cancer Institute (NCI) | 3015 |
| Zentalis | 1 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Brigham and Women's Hospital | Boston | United States | 60 |
| Dana-Farber Cancer Institute | Boston | United States | 626 |